Dennerstein L, Fotherby K, Burrows G D, Laby B, Wood C
Maturitas. 1980 Jul;2(2):147-54. doi: 10.1016/0378-5122(80)90049-3.
Plasma levels of levonorgestrel and ethinyl oestradiol were estimated in six women who took part in a double blind cross-over trial of hormone replacement therapy. Over a 12 mth period, each woman received each of the following oral drugs for 3 mth: ethinyl oestradiol 50 microgram, levonorgestrel 250 microgram, combination of ethinyl oestradiol 50 microgram and levonorgestrel 250 microgram (Nordiol), and placebo. Plasma samples were collected at 2, 8 and 26 h after morning medication each month. Plasma levels of norgestrel were increased when ethinyl oestradiol was added in the form of the combined preparation "Nordiol". The addition of ethinyl oestradiol to norgestrel therapy also resulted in significant differences between patients in the plasma norgestrel levels. There was approximately a three-fold difference between individuals in the plasma levels of ethinyl oestradiol achieved on the same fixed dose. No simple relationship was evident between plasma levels of norgestrel or ethinyl oestradiol and any of the clinical features measured.
对参与激素替代疗法双盲交叉试验的6名女性的血浆左炔诺孕酮和炔雌醇水平进行了评估。在12个月期间，每位女性服用以下每种口服药物3个月：炔雌醇50微克、左炔诺孕酮250微克、炔雌醇50微克与左炔诺孕酮250微克的组合（诺地洛尔）以及安慰剂。每月在早晨服药后2、8和26小时采集血浆样本。当以复方制剂“诺地洛尔”的形式添加炔雌醇时，血浆炔诺孕酮水平升高。在炔诺孕酮治疗中添加炔雌醇也导致患者血浆炔诺孕酮水平存在显著差异。在相同固定剂量下，个体间血浆炔雌醇水平存在约三倍的差异。炔诺孕酮或炔雌醇的血浆水平与所测量的任何临床特征之间均无明显的简单关系。
